Mount Sinai Scientists Unravel How Psychedelic Drugs Interact with Serotonin Receptors to Potentially Produce Therapeutic Benefits
Researchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to produce potential therapeutic effects in patients with neuropsychiatric disorders such as depression and anxiety. In a study published May 8 in Nature, the team reported that certain psychedelic drugs interact with an underappreciated member of the serotonin receptor family in the brain known as 5-HT1A to produce therapeutic benefits in animal models.